Panelists narrowly voted yes on six of seven peptides despite FDA scientists urging no. Emideltide was rejected, and the agency still has the final say.
Recap by typeshit. Full story at LAist.
Strive Specialties failed to revive its suit over GLP-1 competition. Novo still faces soft 2026 forecasts and an exploratory CagriSema analysis in women.
Reports say RFK Jr. backs an interim path for specialty compounding, while the FDA lists BPC-157 as a possible safety risk and doctors cite thin human evidence.
Belga reports the number of seized weight loss drugs in Belgium went up again, with officials concerned about an unofficial parallel market.
Clinics took about 60% of supply, and one Seoul clinic got more Mounjaro than 174 hospitals combined. The health ministry warns of sanctions and criminal referrals.
The show is collecting experiences from people microdosing GLP-1 drugs, including why they tried it and how they got the medication.
Researchers used AI to pull possible safety signals from people who say they take retatrutide, a drug that is still unapproved.
Loading…